MedPath

FDA Approves Minimally Invasive Sacroiliac Joint Fusion Technique Developed by East Texas Surgeon

• Dr. Babajide Ogunseinde received FDA approval for a novel posterior medial to lateral technique to treat sacroiliac joint dysfunction, offering a less invasive option. • The procedure involves a small 2 cm incision and a 3D-printed implant to stabilize and fuse the sacroiliac joints, minimizing soft tissue trauma and blood loss. • Benefits include earlier pain relief, no weight-bearing restrictions post-surgery, and a quick recovery, allowing patients to resume normal activities within days. • This technique addresses a significant cause of lower back pain, particularly in women, overweight individuals, and those with pelvic trauma or multiple pregnancies.

Longview, TX - The U.S. Food and Drug Administration (FDA) has approved a new minimally invasive surgical technique for sacroiliac (SI) joint fusion, developed by Dr. Babajide Ogunseinde, an orthopedic spine surgeon at Longview Orthopedics Regional Clinics in East Texas. This innovative posterior medial to lateral approach offers a less invasive alternative for patients suffering from lower back pain due to sacroiliac joint dysfunction.

Minimally Invasive Approach

Dr. Ogunseinde's technique distinguishes itself from traditional methods by utilizing a single, small 2-centimeter incision. "There are many other techniques that have been published in the spine literature about circular fusion and those involve multiple incisions, longer surgeries," Ogunseinde said. "They're more painful... So this procedure that we started at Longview Regional was inspired by looking for a way to reduce those factors, the pain, the bleeding, the multiple incisions."
The procedure addresses bilateral sacroiliac dysfunction in a single surgery, minimizing soft tissue trauma and blood loss. According to Longview Regional Medical Center, the technology incorporates a specially designed, 3D-printed implant to stabilize and fuse the SI joints, effectively limiting excessive motion.

Improved Patient Outcomes

One of the key advantages of this new technique is the rapid recovery time and reduced post-operative restrictions. "Through this technology, there has been earlier pain relief post-surgery with no weight bearing restrictions after the operation, which offers an improved quality of life when other options have been unsuccessful," Ogunseinde noted.
Patients typically go home the same day on oral pain medication and can shower and drive within one to two days. The anesthesia lasts approximately 20-25 minutes, with a recovery period of about 30 minutes. Patients have reported feeling significantly better within a few days post-surgery.

Addressing Sacroiliac Joint Dysfunction

Sacroiliac joint dysfunction is estimated to be the cause of lower back pain in approximately 30% of patients. Risk factors include being female, overweight, having multiple children, or experiencing trauma to the pelvis or SI joint. "So 10 to 15, years ago, when we didn't know anything about SI joint dysfunction, we just thought patients were not being honest or felt like they had some psychosomatic problems. But now that we know that SI joint is a problem, especially for low back pain... We've had so much success with identifying this and treating this either non-surgically and surgically," Ogunseinde explained.
This FDA-approved procedure represents a significant advancement in the treatment of sacroiliac joint dysfunction, offering a minimally invasive option with the potential for faster recovery and improved quality of life for patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants 510(k) Clearance to RELIEF Stent for Vesicoureteral Reflux

The FDA has approved the RELIEF ureteral stent for preventing vesicoureteral reflux, marking the first such approval in the U.S. The stent, developed by The Ureteral Stent Company, aims to address the significant side effects associated with current stents, such as reflux and bladder spasms, through its unique design.

Pacira Receives FDA Clearance for Iovera System to Treat Chronic Back Pain

Pacira BioSciences has received FDA clearance for its Iovera system with a longer-needle Smart Tip to treat chronic low back pain, offering a drug-free alternative.
The Iovera system uses cryoneurolysis to temporarily halt nerve signals, providing pain relief that can last for months, and has shown benefits in a pilot study.

SeaStar Medical's Selective Cytopheretic Device Receives FDA Breakthrough Designation for ESRD Inflammation

SeaStar Medical's Selective Cytopheretic Device (SCD) has been granted Breakthrough Device designation by the FDA for treating inflammation in end-stage renal disease (ESRD).
The SCD targets and neutralizes pro-inflammatory cytokines, aiming to mitigate hyperinflammation and improve clinical outcomes in ESRD patients.

FDA Clears Foundation Surgical's Vertiwedge® Intraosseous System for Vertebral Body Replacement

The FDA has granted 510(k) clearance to Foundation Surgical's Vertiwedge® Intraosseous System, a novel device for partial vertebral body replacement in the thoracolumbar spine.
Indicated for use in T1-L5, the device addresses conditions like trauma, fractures, tumors, and degenerative spine disease by restoring vertebral height.

Ochsner LSU Health Surgeon Performs First Gore Excluder TAMBE Procedure in Louisiana

Dr. Chiranjiv Virk successfully performed Louisiana's first Gore Excluder TAMBE procedure, a new innovation in aortic aneurysm treatment.
The FDA-approved device allows for a minimally invasive approach, reducing risks associated with traditional open surgery for aortic aneurysms.

NeurAxis Receives Expanded FDA Clearance for IB-Stim in Abdominal Pain Relief

NeurAxis has secured an expanded FDA 510(k) clearance for its IB-Stim device, a non-implanted nerve stimulator, to broaden its application in functional abdominal pain relief.
The expanded clearance increases the addressable market for IB-Stim by approximately 75% and allows for the use of up to four devices per patient, according to NeurAxis.

L&K Biomed's BluEX Lumbar Expandable Cage System Receives FDA Approval

L&K Biomed secured FDA 510(k) clearance for its BluEX Lumbar Expandable Cage System, designed for enhanced bone integration and versatile surgical approaches.
The BluEX system features six cage designs adaptable for anterior, posterior, lateral, ATP, and endoscopic lumbar approaches, offering surgeons greater flexibility.

FDA Approves Distalmotion's Dexter Surgical Robot for Inguinal Hernia Repair

Distalmotion's Dexter Surgical Robot receives FDA De Novo approval for adult inguinal hernia repair, marking a step in expanding robotic surgery access.
Dexter is designed for high-volume procedures in outpatient settings, addressing the growing demand for cost-effective robotic solutions.

SpineGuard's PsiFGuard Receives FDA Clearance for Sacroiliac Joint Fusion

SpineGuard's PsiFGuard, a smart drilling device for posterior sacroiliac fusion (PsiF), has received FDA 510(k) clearance for commercial use in the United States.
The PsiFGuard device utilizes SpineGuard's Dynamic Surgical Guidance (DSG®) technology to enhance the accuracy of implant placement in SI joint fusion procedures.

Medtronic's Inceptiv Spinal Cord Stimulator Receives FDA Approval for Chronic Pain Relief

Medtronic's Inceptiv, a spinal cord stimulator, has gained FDA approval for managing chronic pain by automatically adjusting stimulation based on biological signals.
The device is implanted and works by sensing signals and blocking pain signals before they reach the brain, offering a potential alternative to traditional pain management.

Reference News

[1]
East Texas doctor gets FDA approval for new back pain procedure | cbs19.tv
cbs19.tv · Dec 18, 2024

Dr. Babajide Ogunseinde designed an FDA-approved technique for treating sacroiliac joint dysfunction, offering a minimal...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy